Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group

Caitlin W. Elgarten, Joel C. Thompson, Anne Angiolillo, Zhiguo Chen, Susan Conway, Meenakshi Devidas, Sumit Gupta, John A. Kairalla, Jennifer L. McNeer, Maureen M. O'Brien, Karen R. Rabin, Rachel E. Rau, Susan R. Rheingold, Cindy Wang, Charlotte Wood, Elizabeth A. Raetz, Mignon L. Loh, Sarah Alexander, Tamara P. Miller

Research output: Contribution to journalArticlepeer-review

Abstract

Infections cause substantial morbidity for children with acute lymphoblastic leukemia (ALL). Therefore, accurate characterization of infectious adverse events (AEs) reported on clinical trials is imperative to defining, comparing, and managing safety and toxicity. Here, we describe key processes implemented to improve reporting of infectious AEs on two active phase III Children's Oncology Group (COG) ALL trials. Processes include: (a) identifying infections as a targeted toxicity, (b) incorporation of infection-specific case report form questions, and (c) physician review of AEs with real-time data cleaning. Preliminary assessment of these processes suggests improved reporting, as well as opportunities for further improvement.

Original languageEnglish
Article numbere29937
JournalPediatric Blood and Cancer
Volume69
Issue number11
DOIs
StatePublished - Nov 2022
Externally publishedYes

Keywords

  • acute lymphoblastic leukemia
  • adverse events
  • clinical trials
  • infections

Fingerprint

Dive into the research topics of 'Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group'. Together they form a unique fingerprint.

Cite this